factual
Pharma has externalized R&D to a biotech-startup ecosystem
Large pharma operates like venture capital firms, externalizing early R&D to nimble biotech startups: roughly 70% of approved molecules originate in small biotechs even though most R&D dollars sit on big-pharma balance sheets, with pharma acting as an oligopsony of buyers for phase-one/phase-two-ready assets and running the expensive trials that account for much of the cost difference.
factualpending
Speaker
Jacob KimmelEvidence Quote
“you can think about some of the modern pharmas a bit like venture capital firms. They've over time externalized a lot of their R&D.”
Created: 6/13/2026, 3:28:32 AM
Your notes
Loading notes...